For many years as a practicing cardiologist it was apparent that in general when leveling out all additional risk factors, middle-aged men had more heart disease than middle-aged women. I doubt that this comes as a surprise to anyone. However, this increased incidence in men versus women did not comparatively stay the same forever. After menopause, the incidence of heart disease in women began to increase such that at ten years or so down the road, the relative incidence began leveling out. In other words it appeared that the female’s hormones served a protective function, and as they disappeared, this protection also disappeared.
Now what do you think might happen as far as an individual’s risk of heart disease when hormones are artificially manipulated at young age? Do men who are given estrogen then begin the behave as women as far as the heart is concerned? And likewise do women given testosterone at a young age then begin to assume a heart disease risk commensurate with men of the same age?
Recently a study was done on transvestites and their risk of heart disease. [In order to try to keep the different terms clear, AFAB refers to individuals who were born female (Assigned Female At Birth), and AMAB refers to individuals who were born male.]
Dr. Dorte Glintborg of Denmark’s Odense University Hospital noted in a 2021 study that “epidemiological studies in transgender women (AMAB) reported increased risk of acute myocardial infarction and stroke during feminizing treatment, whereas long-term, controlled studies regarding feminizing treatment and risk of arterial CVD are lacking.”
In an apparent follow-up last month, Glintborg determined that male transvestites (AMAB) taking cross-sex hormones were nearly twice as likely to suffer from any cardiovascular disease as men not taking hormones, reported the Telegraph.
In other words, this new study published in the European Journal of Endocrinology revealed that male transvestites (AMAB) taking feminizing hormones are 93% more likely to suffer heart disease than other men. Female transvestites (AFAB) taking testosterone are 63% more likely to suffer heart disease than other women.
While men are especially at risk, all individuals undergoing cross-sex conversion therapy face “significantly increased risk” of heart attacks, strokes, high blood pressure, and high cholesterol levels.
In addition, a article, published on 9/23/23 in the European Journal of Endocrinology, also with Dr. Glintborg as the lead author concluded the following:
The OR (odds ratio) for mental health disorders was higher in transgender persons compared to controls and remained elevated throughout follow up, especially in transgender persons AMAB.
Hopefully these results of Dr. Glintborg’s studies will soon make their way into our Main Stream Media … but don’t hold your breath!
10/7/23